论文部分内容阅读
目的观察曲美他嗪治疗冠心病合并糖尿病的临床效果。方法将冠心病合并糖尿病的患者84例随机分为治疗组和对照组,各42例。对照组采用常规药物治疗;治疗组在常规药物基础上加用曲美他嗪治疗。对比2组临床疗效,冠心病症状消失时间、心电图检查结果恢复正常时间、治疗时间,用药前后心功能相关指标水平和不良反应。结果治疗组总有效率为90.5%高于对照组的69.0%,差异有统计学意义(P<0.05)。治疗组冠心病症状消失时间、心电图检查结果恢复正常状态时间和治疗时间均短于对照组,差异均有统计学意义(P<0.05)。用药前2组左心室射血分数、左心室短轴缩短率比较差异无统计学意义(P>0.05);治疗后,2组心功能相关指标水平均改善,但治疗组相关指标水平改善幅度明显大于对照组,差异均有统计学意义(P<0.05)。治疗组不良反应发生率为2.4%(1/42)低于对照组的21.4%(9/42),差异有统计学意义(P<0.05)。结论曲美他嗪治疗冠心病合并糖尿病患者的临床效果非常明显,值得临床推广应用。
Objective To observe the clinical effect of trimetazidine in the treatment of coronary heart disease complicated with diabetes. Methods 84 cases of coronary heart disease with diabetes were randomly divided into treatment group and control group, 42 cases in each. The control group was treated with conventional drugs. The treatment group was treated with trimetazidine based on conventional drugs. The clinical efficacy, duration of disappearance of symptoms of coronary heart disease, ECG normalization time, treatment time, cardiac function-related index and adverse reactions before and after treatment were compared between two groups. Results The total effective rate in the treatment group was 90.5% higher than that in the control group (69.0%), the difference was statistically significant (P <0.05). The treatment group, coronary heart disease disappeared, electrocardiogram results returned to normal state time and treatment time were shorter than the control group, the difference was statistically significant (P <0.05). There was no significant difference in left ventricular ejection fraction and left ventricular short axis shortening rate between the two groups before treatment (P> 0.05). After treatment, the levels of cardiac function related indexes in both groups were improved, but the improvement rate of the relevant indexes in the treatment group was significantly Compared with the control group, the differences were statistically significant (P <0.05). The incidence of adverse reactions in the treatment group was 2.4% (1/42), which was lower than that in the control group (21.4%, 9/42). The difference was statistically significant (P <0.05). Conclusion Trimetazidine treatment of coronary heart disease patients with diabetes is very obvious clinical effect, it is worthy of clinical application.